Table 3.
Subgroup Analysis By Serum Fibrinogen For Overall Survival In Patients With Esophageal Squamous Cell Carcinoma
| Prognostic Factors | Overall Survival | |
|---|---|---|
| Mean(m) | p | |
| Age(years) | ||
| ≤63 | 0.011* | |
| Normal level | 30.76 | |
| Hyperfibrinogenemia | 27.21 | |
| >63 | 0.201 | |
| Normal level | 29.33 | |
| Hyperfibrinogenemia | 27.44 | |
| Sex | ||
| Female | 0.002* | |
| Normal level | 31.06 | |
| Hyperfibrinogenemia | 25.74 | |
| Male | 0.180 | |
| Normal level | 29.43 | |
| Hyperfibrinogenemia | 27.90 | |
| Smoking (7 missing data) | ||
| Never | <0.001* | |
| Normal level | 31.05 | |
| Hyperfibrinogenemia | 25.42 | |
| Ever/current | 0.180 | |
| Normal level | 29.43 | |
| Hyperfibrinogenemia | 27.90 | |
| Alochol (20 missing data) | ||
| Never | <0.001* | |
| Normal level | 31.15 | |
| Hyperfibrinogenemia | 26.39 | |
| Ever/current | 0.844 | |
| Normal level | 28.72 | |
| Hyperfibrinogenemia | 28.31 | |
| pT stage | ||
| T1-2 | 0.123 | |
| Hyperfibrinogenemia | 31.79 | |
| Ever/current | 28.98 | |
| T3-4 | 0.065 | |
| Hyperfibrinogenemia | 28.77 | |
| Ever/current | 26.49 | |
| pN stage | ||
| N0 | 0.002* | |
| Hyperfibrinogenemia | 32.53 | |
| Ever/current | 29.34 | |
| N1-3 | 0.323 | |
| Hyperfibrinogenemia | 26.50 | |
| Ever/current | 24.62 | |
| pTNM staging | ||
| Stage I-II | 0.004* | |
| Hyperfibrinogenemia | 32.01 | |
| Ever/current | 28.96 | |
| Stage III | 0.303 | |
| Hyperfibrinogenemia | 26.93 | |
| Ever/current | 25.10 | |
Note: *Statistically significant (p<0.05).
Abbreviations: m, month; CI, confidence interval; pTNM, pathological tumor/node/metastasis.